c-Fms

CSF-1 receptor; colony stimulating factor 1 receptor; CSF-1R; CSF1R

c-Fms

Related Products

c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. c-FMS is the cell surface receptor for IL-34 and CSF1. c-FMS has important roles in haematopoiesis, regulation of proliferation, cell survival and maturation of microglia and monocytes, as well as in controlling the overall immune response.

c-FMS is specifically expressed in osteoclasts and myelomonocytic-lineage cells, such as monocytes and macrophages, and the activation of c-FMS signaling promotes the proliferation or differentiation of these cells. It also promotes the production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL6).

c-Fms Related Products (126)
Recombinant Proteins (27)
Antibodies (8)

By Effects:	Inhibitors (111) Antagonist (1) Chemical (1) Inducers (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-13075

c-Fms-IN-3	Inhibitor	99.69%
c-Fms-IN-3 is an orally active c-Fms (CSF1R) kinase inhibitor (IC₅₀ = 0. 8 nM). c-Fms-IN-3 inhibits CSF1R kinase activity and reduces macrophage populations. c-Fms-IN-3 reduces bone erosion, pannus invasion, cartilage damage, and inflammation in collagen (HY-NP003)-induced arthritis mouse model. c-Fms-IN-3 is useful for arthritis research.

HY-132935A

BPR1R024 mesylate	Inhibitor
BPR1R024 mesylate is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 mesylate is the equivalent of BPR1R024 (HY-132935). BPR1R024 has potent CSF1R inhibition activity with an IC₅₀ value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology.

HY-148181

c-Fms-IN-13	Inhibitor	99.27%
c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor with an IC₅₀ value of 17 nM. c-Fms-IN-13 can be used as an anti-inflammatory agent.

HY-10917S

GW2580-d₆	Inhibitor	98.36%
GW2580-d6 is the deuterium labeled GW2580. GW2580 is an orally bioavailable and selective inhibitor of c-Fms kinase which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling.

HY-P99642

Gimsilumab	Inhibitor	98.00%
Gimsilumab (MORAb-022) is a human anti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA).

HY-159503

Segigratinib	Inhibitor
Segigratinib is a fibroblast growth factor receptor tyrosine kinase inhibitor, with antineoplastic effect.

HY-12768B

Sotuletinib dihydrochloride	Inhibitor
Sotuletinib (BLZ945) dihydrochloride is an orally active and blood-brain barrier-permeable CSF1-R-specific inhibitor (IC₅₀=1 nM). Sotuletinib (BLZ945) dihydrochloride induces tumor cell apoptosis and effectively inhibits tumor growth in mouse models. Sotuletinib dihydrochloride can be used in cancer and amyotrophic lateral sclerosis (ALS) research.

HY-153277

Axl/Mer/CSF1R-IN-2	Inhibitor
Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and CSF1R inhibitor.

HY-153243

IACS-9439	Inhibitor
IACS-9439 is a potent, selective, and orally active CSF1R inhibitor with a K_i value of 1 nM inhibitor. IACS-9439 can be used for advanced solid tumors research.

HY-111248

ABD-295	Inhibitor
ABD-295, a biphenylsulfide derivative, is an antiresorptive agent, osteoclast inhibitor. ABD-295 has potent inhibitory effects on osteoclastic bone resorption in vitro. ABD-295 prevents ovariectomy-induced bone loss in vivo^{[1]^.}

HY-144041

CSF1R-IN-5	Inhibitor
CSF1R-IN-5 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11).

HY-147608

CSF1R-IN-7	Inhibitor
CSF1R-IN-7 (Formula I) is a CSF-1R inhibitor. CSF1R-IN-7 can be used for Alzheimer’s disease research.

HY-147610

CSF1R-IN-9	Inhibitor
CSF1R-IN-9 (Compound 46) is a CSF-1R inhibitor with an IC₅₀ of 0.028 μM.

HY-155550

CSF1R-IN-17	Antagonist
CSF1R-IN-17 (compound 9) is a potent and selective CSF1R antagonist, with an IC₅₀ of 0.2 nM. CSF1R-IN-17 can inhibit osteoclast differentiation.

HY-147617

CSF1R-IN-14
CSF1R-IN-14 is an isoindolinone derivative compound. CSF1R-IN-14 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-14 has the potential for the research of cancer diseases (extracted from patent WO2019134662A1, compound 1).

HY-158148

CSF1R-IN-23	Inhibitor
CSF1R-IN-23 (Compound 7dri) is a selective inhibitor for colony-stimulating factor-1 receptor (CSF1R), with IC₅₀ of 36.1 nM. CSF1R-IN-23 serves as antineuroinflammatory agent in mouse model. CSF1R-IN-23 is blood brain barrier (BBB) permeable.

HY-144040

CSF1R-IN-4
CSF1R-IN-4 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-4 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-4 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 104).

HY-108162A

Ataquimast	Inhibitor
Ataquimast is a COX-2 inhibitor that inhibits the release of leukotrienes, TNF-α and GM-CSF. Ataquimast can be used in the study of advanced receptor-positive breast cancer.

HY-P99458

Balugrastim
Balugrastim (CG 10639) is a novel long-acting recombinant granulocyte colony-stimulating factor (G-CSF) obtained by means of a genetic fusion between recombinant human serum albumin and granulocyte colony-stimulating factor. Balugrastim can be used for the research of breast cancer.

HY-147864

c-Fms-IN-12	Inhibitor
c-Fms-IN-12 (Compound 4g) is an FMS kinase inhibitor. c-Fms-IN-12 can also inhibits c-KIT. c-Fms-IN-12 is a potential broad-spectrum anticancer agent against multiple cancer types. c-Fms-IN-12 induces A549 cell apoptosis.

Name
Email *

	Sorry, but the email address you supplied was invalid.

c-Fms

c-Fms

c-Fms Related Products (126)

Recombinant Proteins (27)

Antibodies (8)

c-Fms Related Products (126):